( MENAFN - PR Newswire) SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International convention 2024, which is taking place here in San Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 antibody, codenamed FP008. This fusion protein provides a promising therapeutic strategy for solid tumors refractory to anti-PD-1 therapy. The groundbreaking announcement is a testimony to Fapon Biopharma's strength in developing anticancer drugs.
FP008 is a patent-pending drug candidate developed by Fapon Biopharma using cutting-edge antibody technology. It stands out as a first-in-class biologic candidate combining IL-10M (an attenuated IL-10 monomer variant) and an anti-PD-1 antibody, providing a targeted therapy with enhanced efficacy while significantly reducing the challenging toxicity associated with wtIL-10. This is a critical advancement in the field.
FP008 not only reduces the apoptosis of the exhausted CD8+ T cells and restores their activity in vitro, but also significantly increases the level of CD8+ T cells within the tumor microenvironment, exhibiting a potent anti-tumor effect in vivo. It exhibited good druggability and was well tolerated in a toxicity study of up to 10 mpk in cynomolgus monkeys. As a result, FP008 is a viable drug candidate.
FP008 is poised to have a substantial impact on immunotherapy for cancer in patients who do not respond to.
